Senescence is defined as a deterioration of function with age. Senolytic drugs clear senescent (ageing) cells from the body and reduce inflammation. These, and other geroprotector drugs are of increasing interest in preventing or reducing the negative effects of ageing on organs, tissues and cells. Digoxin is a drug commonly used to control atrial fibrillation. Animal models suggest digoxin is a senolytic. If digoxin was used as a senolytic, it would be a repurposed use of the drug, where digoxin is used for another indication rather than the one it is commonly prescribed for.
Community acquired pneumonia (CAP) is a common cause of hospitalisation in older adults and is increasingly recognised as a severe consequence of senescence. There is some evidence to suggest people on digoxin are protected from severe consequences of CAP.
PIONEER, working with HDRUK Medicines programme, have curated a highly granular dataset of 63,664 CAP admissions. The data includes demography, comorbidities, presenting symptoms, serial physiology, investigations, medications and outcomes. It focuses on a cohort who are and are not taking digoxin.
Geography: The West Midlands (WM) has a population of 6 million & includes a diverse ethnic & socio-economic mix. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.
Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact [email protected] or visit www.pioneerdatahub.co.uk for more details.
Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in OMOP and other common data models and can build synthetic data to meet bespoke requirements.
Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment (TRE) build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.
Further information including technical details, coverage, format and standards, provenance and related resources can be found on the link below: https://healthdatagateway.org/en/dataset/943
